DaVita (DVA)

Dialysis is a recurring, medically necessary service, and DaVita’s scale gives it an important role in the US healthcare system. The company treats hundreds of thousands of patients each year through a network of more than 3,000 facilities worldwide, with most of its operations located in the United States. Its services typically include in-centre haemodialysis, support for home dialysis, clinical care coordination, and related patient services.

The economics of DaVita’s business are closely tied to reimbursement. In the United States, Medicare and other government payers cover a large share of dialysis patients, meaning regulated reimbursement rates are a major factor in revenue. Commercially insured patients represent a much smaller portion of the patient base, but they are especially important to profitability because commercial reimbursement is generally higher than government rates.

DaVita competes in a highly regulated healthcare market where clinical quality, treatment access, payer relationships, labour costs, and government policy all matter. Its size, clinic density, physician relationships, and operational experience make it one of the defining companies in US dialysis care, while also exposing it to ongoing scrutiny over healthcare costs and reimbursement practices.